ADMA (STOCKS)
ADMA Biologics, Inc.
$10.390000
+0.690000 (+7.11%)
Prev close: $9.700000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Adam S. Grossman
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $2,470.90M
- Employees
- 685
- P/E (TTM)
- 16.17
- P/B (TTM)
- 4.83
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
2
Strong Buy
5
Buy
2
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$0.20 | $0.19 | +0.0113 | +5.99% |
|
Sep 2025 (Q3)
|
$0.15 | $0.15 | -0.0030 | -1.96% |
|
Jun 2025 (Q2)
|
$0.14 | $0.14 | -0.0028 | -1.96% |
|
Mar 2025 (Q1)
|
$0.11 | $0.16 | -0.0498 | -31.16% |
Financial Statements
| Revenues | $510.17M |
| Benefits Costs and Expenses | $327.52M |
| Cost Of Revenue | $217.41M |
| Costs And Expenses | $327.52M |
| Gross Profit | $292.77M |
| Nonoperating Income/Loss | -$8.79M |
| Operating Expenses | $101.32M |
| Selling, General, and Administrative Expenses | $91.58M |
| Depreciation and Amortization | $8.10M |
| Research and Development | $4.76M |
| Operating Income/Loss | $191.44M |
| Income/Loss From Continuing Operations After Tax | $146.93M |
| Income/Loss From Continuing Operations Before Tax | $182.66M |
| Income Tax Expense/Benefit | $35.73M |
| Income Tax Expense/Benefit, Current | $24.71M |
| Income Tax Expense/Benefit, Deferred | $11.02M |
| Net Income/Loss | $146.93M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | $146.93M |
| Net Income/Loss Available To Common Stockholders, Basic | $146.93M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | $0.62 |
| Diluted Earnings Per Share | $0.60 |
| Basic Average Shares | 238,299,024 |
| Diluted Average Shares | 244,904,640 |
| Assets | $624.24M |
| Current Assets | $466.51M |
| Inventory | $206.47M |
| Other Current Assets | $260.05M |
| Noncurrent Assets | $157.73M |
| Fixed Assets | $65.06M |
| Intangible Assets | $632.00K |
| Other Non-current Assets | $92.04M |
| Liabilities | $146.92M |
| Current Liabilities | $69.54M |
| Accounts Payable | $22.52M |
| Other Current Liabilities | $47.02M |
| Noncurrent Liabilities | $77.38M |
| Long-term Debt | $72.14M |
| Other Non-current Liabilities | $5.24M |
| Equity | $477.32M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $477.32M |
| Liabilities And Equity | $624.24M |
| Net Cash Flow From Operating Activities | $50.40M |
| Net Cash Flow From Operating Activities, Continuing | $50.40M |
| Net Cash Flow From Investing Activities | -$21.89M |
| Net Cash Flow From Investing Activities, Continuing | -$21.89M |
| Net Cash Flow From Financing Activities | -$44.02M |
| Net Cash Flow From Financing Activities, Continuing | -$44.02M |
| Net Cash Flow | -$15.52M |
| Net Cash Flow, Continuing | -$15.52M |
| Comprehensive Income/Loss | $146.93M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | $146.93M |
| Other Comprehensive Income/Loss | $0.00 |